Previous 10 | Next 10 |
Taiwan Liposome (NASDAQ: TLC ): Q3 GAAP EPS of -$0.09 beats by $0.13 . More news on: Taiwan Liposome Company, Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 22, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, today announ...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 21, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, recently...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 20, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in p...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 07, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in p...
- Phase II results showed statistically significant pain relief through 24 weeks - Phase III to evaluate efficacy of single and repeated doses up to 52 weeks SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 01, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-st...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 23, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in ...
The following slide deck was published by Taiwan Liposome Company, Ltd. in conjunction with this Read more ...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 03, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152) announced today that the Company’s management team has been invited to participate in the BTIG Pain Management Forum on September 11, 2019, where TLC will present data on...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 28, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152) today announced that the management team is scheduled to present at the two upcoming investor conferences: Baird Global Healthcare Conference Dates: ...
News, Short Squeeze, Breakout and More Instantly...
Taiwan Liposome Company Ltd. Company Name:
TLC Stock Symbol:
NASDAQ Market:
Taiwan Liposome Company Ltd. Website:
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Professor David Hunter, Florance and Cope Chair of Rheumatology at the University of Sydney, presented detailed findings from the Phase 3 clinical trial of TLC599 at the American College of Rheumatology (ACR) Annual...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 08, 2023 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a late clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical needs in orthopedic disorders, today announced that the Abstract Sele...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 13, 2022 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that it has entered a commercialization agreem...